Hodgkin'S Disease in Northern Sweden 1971-1981 Ii. A Retrospective Analysis of Prognostic Factors

References

• Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medico-Chirurgical Transactions 1832; 17: 68–114
   PubMedGoogle Scholar
• Nordentoft A M, Pedersen-Bjergaard J, Brinckler H, et al. Hodgkin's disease in Denmark. A national clinical study by the Danish Hodgkin study group, LYGRA. Scand J Haematol 1980; 24: 321–34
   PubMedGoogle Scholar
• Wedelin C, Björkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 1984; 53: 1202–8
   PubMed Web of Science ®Google Scholar
• Hancock B W, Aitken M, Martin J F, et al. Hodgkin's disease in Sheffield (1971–76) (with computer analysis of variables). Clin Oncol 1979; 5: 283–97
   PubMed Web of Science ®Google Scholar
• Lokich J J, Pinkus G S, Moloney WC. Hodgkin's disease in the elderly. Oncology 1974; 5: 484–500
   Google Scholar
• Eghbali H, Hoerni-Simon G, de Mascarel I, Durand M, Chauvergne J, Hoerni B. Hodgkin's disease in the elderly—A series of 30 patients aged older than 70 years. Cancer 1984; 53: 2191–3
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Steward W, Jones M, et al. Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematol Oncol 1986; 4: 135–47
   PubMed Web of Science ®Google Scholar
• Tubiana M, Henry-Amar M, van der Werf-Messing B, et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985; 11: 23–30
   PubMed Web of Science ®Google Scholar
• Horwich A, Easton D, Nogueira-Costa R, Liew K H, Colman, Peckham MJ. An analysis of prognostic factors in early stage Hodgkin's disease. Radiother Oncol 1986; 7: 95–106
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Kaplan H S, Glatstein E, Portlock CS. Combined modality treatment of Hodgkin's disease: A report on the Stanford trials. Cancer 1978; 42: 991–1000
   PubMed Web of Science ®Google Scholar
• De Vita V T, Simon R M, Hubbard S M, et al. Curability of Hodgkin's disease with chemotherapy: Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980; 92: 587–95
   PubMed Web of Science ®Google Scholar
• Bonnadonna G, Zuculi K, Monfardini S, de Lena M, Uslengi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carbox-imide versus MOPP. Cancer 1975; 36: 252–9
   PubMed Web of Science ®Google Scholar
• Fuller L M, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer 1983; 51: 2469–76
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Kaplan H S, Hoppe R T, Kushlan P, Horning S. An overview of the rationale and results of Stanford randomized trials of the treatment of Hodgkin's disease 1967–1980. Adjuvant therapy of cancer. III, S E Salmon, E J Jones. Grune and Stratton, New York 1981; 65–76
   Google Scholar
• Tura S, Mazza P, Zinzani P L, et al. Hodgkin's disease (HD): A historical perspective. Eur J Clin Oncol 1986; 22: 1315–23
   PubMedGoogle Scholar
• DeVita V. The consequences of the chemotherapy of Hodgkin's disease. Cancer 1981; 47: 1–13
   PubMed Web of Science ®Google Scholar
• Bonnadonna G, Santora A. Drug selection in the treatment of Hodgkin's disease. Hematol Oncol 1983; 1: 3–12
   PubMedGoogle Scholar
• Dige U, Johansson H, Lenner P, Norberg B, Roos G. Hodgkin's disease in Northern Sweden 1971–1981. I. A histo-pathological review of 223 cases. Acta Oncol 1991; 30: 593–6
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshof K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1970; 31: 1860–1
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I: Introduction and design. Br J Cancer 1976; 34: 565–612
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clincial trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Statist Soc B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Ederer F, Axtell L M, Cutler SJ. The relative survival rate: A statistical methodology. In: National Cancer Institute Monogr 1961; 6: 101–21
   PubMedGoogle Scholar
• Hakulinen T. On long-term relative survival rates. J Chron Dis 1977; 30: 431–43
   PubMedGoogle Scholar
• Norberg B, Dige U, Roos G, Johansson H, Lenner P. Hodgkin's disease in northern Sweden 1971–1981. III. the clinical and prognostic impact of age. Acta Oncol 1991; 30, (Accepted for publication)
   Web of Science ®Google Scholar
• Rubin P, Zagars G, Chuang C, Thomas EM. Hodgkin's disease: Is there a price for successful treatment? A 25-year experience. Int J Radiat Oncol Biol Phys 1986; 12: 153–66
   PubMed Web of Science ®Google Scholar
• MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 1966; 26: 1189–200
   PubMed Web of Science ®Google Scholar
• Gallo R C, Gelmann EP. In search of a Hodgkin's disease virus. New Eng J Med 1981; 304: 169–70
   PubMed Web of Science ®Google Scholar
• Gutensohn NM. Social class and age at diagnosis of Hodgkin's disease. New epidemiologic evidence for the 'two-disease hypothesis'. Cancer Treat Rep 1982; 66: 689–95
   PubMedGoogle Scholar